Literature DB >> 26587464

Lipoprotein(a) and Arterial Stiffness Parameters.

Alexander Sorokin1, Kazuhiko Kotani2.   

Abstract

BACKGROUND: Circulating lipoprotein(a) [Lp(a)] and arterial stiffness are markers associated with the atherosclerotic processes. With regard to cardiovascular outcomes, the relationship between Lp(a) and arterial stiffness has not been sufficiently summarized. The present review focuses on the existing association between Lp(a) and arterial stiffness parameters.
SUMMARY: This review included human clinical studies that were published between 1980 and 2015. The metrics of arterial stiffness parameters, 'pulse wave velocity' (PWV) and 'cardio-ankle vascular index' (CAVI), were used for this search, which yielded only 4 cross-sectional studies on this topic. Of these 4 studies, 3 reports were based on the use of PWV, while 1 study was based on the use of CAVI. Three studies (including the study using CAVI) reported that high Lp(a) levels were positively associated with arterial stiffness.
CONCLUSION: The present review indicates a positive association between Lp(a) and arterial stiffness, as assessed by PWV and CAVI. To definitively establish these findings, there is a need for further prospective outcome studies that simultaneously measure Lp(a) and the oxidative form of Lp(a) (as a pathological marker) as well as PWV and CAVI.

Entities:  

Keywords:  Apolipoprotein(a); Cardio-ankle vascular index; Lipoprotein(a); Oxidized lipoprotein(a); Pulse wave velocity

Year:  2015        PMID: 26587464      PMCID: PMC4646143          DOI: 10.1159/000438733

Source DB:  PubMed          Journal:  Pulse (Basel)        ISSN: 2235-8668


  31 in total

Review 1.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis.

Authors:  A Undas; E Stepien; W Tracz; A Szczeklik
Journal:  J Thromb Haemost       Date:  2006-05       Impact factor: 5.824

Review 3.  Blood pressure and pulse wave velocity as metrics for evaluating pathologic ageing of the cardiovascular system.

Authors:  Peter M Nilsson; Payam Khalili; Stanley S Franklin
Journal:  Blood Press       Date:  2013-06-10       Impact factor: 2.835

Review 4.  Lipoprotein(a) as a therapeutic target in cardiovascular disease.

Authors:  Marlys Koschinsky; Michael Boffa
Journal:  Expert Opin Ther Targets       Date:  2014-05-22       Impact factor: 6.902

Review 5.  Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives.

Authors:  Kohji Shirai; Noriyuki Hiruta; Mingquiang Song; Takumi Kurosu; Jun Suzuki; Takanobu Tomaru; Yoh Miyashita; Atsuto Saiki; Mao Takahashi; Kenji Suzuki; Masanobu Takata
Journal:  J Atheroscler Thromb       Date:  2011-05-31       Impact factor: 4.928

6.  Comparison of arteriosclerotic indicators in patients with ischemic stroke: ankle-brachial index, brachial-ankle pulse wave velocity and cardio-ankle vascular index.

Authors:  Naoki Saji; Kazumi Kimura; Yoshiki Yagita; Toshitaka Kawarai; Hirotaka Shimizu; Yasushi Kita
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

Review 7.  The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease.

Authors:  A E Bochem; J A Kuivenhoven; E S G Stroes
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Association between serum lipoprotein (a) level and progression of non-proliferative diabetic retinopathy in Type 2 diabetes.

Authors:  Hideharu Funatsu; Erika Shimizu; Hidetaka Noma; Tatsuya Mimura; Sadao Hori
Journal:  Acta Ophthalmol       Date:  2008-08-12       Impact factor: 3.761

Review 9.  Lipoprotein(a), cardiovascular disease, and contemporary management.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

10.  The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a).

Authors:  Kazuhiko Kotani; Shingo Yamada; Toshiyuki Yamada; Nobuyuki Taniguchi; Ikunosuke Sakurabayashi
Journal:  Lipids Health Dis       Date:  2011-10-04       Impact factor: 3.876

View more
  3 in total

1.  Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

Authors:  Kazuhiko Kotani; Maciej Banach
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

2.  Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease.

Authors:  Xulong Sun; Ruifang Chen; Guangyu Yan; Zhiheng Chen; Hong Yuan; Wei Huang; Yao Lu
Journal:  PeerJ       Date:  2020-08-18       Impact factor: 2.984

3.  Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study.

Authors:  Arrigo F G Cicero; Federica Fogacci; Giuseppe Derosa; Angela D'Angelo; Fulvio Ventura; Elisabetta Rizzoli; Sergio D'Addato; Claudio Borghi
Journal:  Biomedicines       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.